The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma
Open accessAbstract
Purpose: Most neuroblastomas initially respond to therapy but many relapse with chemoresistant disease. p53 mutations are rare in diagnostic neuroblastomas, but we have previously reported inactivation of the p53/MDM2/p14ARF pathway in 9 of 17 (53%) neuroblastoma cell lines established at relapse. Hypothesis: Inactivation of the p53/MDM2/p14ARF pathway develops during treatment and contributes to neuroblastoma relapse. Methods: Eighty-four neuroblastomas were studied from 41 patients with relapsed neuroblastoma including 38 paired neuroblastomas at different stages of therapy. p53 mutations were detected by automated sequencing, p14ARF methylation and deletion by methylation-specific PCR and duplex PCR, respectively, and MDM2 amplification by fluorescent in situ hybridization. Results: Abnormalities in the p53 pathway were identified in 20 of 41 (49%) cases. Downstream defects due to inactivating missense p53 mutations were identified in 6 of 41 (15%) cases, 5 following chemotherapy and/or at relapse and 1 at diagnosis, postchemotherapy, and relapse. The presence of a p53 mutation was independently prognostic for overall survival (hazard ratio, 3.4; 95% confidence interval, 1.2–9.9; P = 0.02). Upstream defects were present in 35% of cases: MDM2 amplification in 3 cases, all at diagnosis and relapse and p14ARF inactivation in 12 of 41 (29%) cases: 3 had p14ARF methylation, 2 after chemotherapy, and 9 had homozygous deletions, 8 at diagnosis and relapse. Conclusions: These results show that a high proportion of neuroblastomas which relapse have an abnormality in the p53 pathway. The majority have upstream defects suggesting that agents which reactivate wild-type p53 would be beneficial, in contrast to those with downstream defects in which p53-independent therapies are indicated. Clin Cancer Res; 16(4); 1108–18
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
Zhang, Y., Xiong, Y., & Yarbrough, W. G. (1998) · Cell · doi:10.1016/s0092-8674(00)81401-4 · Cited by 1,626
Association of p19ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53
Honda, R., & Yasuda, H. (1999) · The EMBO Journal · doi:10.1093/emboj/18.1.22 · Cited by 724
Robertson, K. D., & Jones, P. A. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.11.6457 · Cited by 352
Cited by
Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations
Eleveld, T. F., Oldridge, D. A., Bernard, V., Koster, J., Daage, L. C., Diskin, S. J., Schild, L., Bentahar, N. B., Bellini, A., Chicard, M., et al. (2015) · Nature Genetics · doi:10.1038/ng.3333 · Cited by 540
Advancing therapy for neuroblastoma
Qiu, B., & Matthay, K. K. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00643-z · Cited by 407
Bresler, S. C., Weiser, D. A., Huwe, P. J., Park, J. H., Krytska, K., Ryles, H., Laudenslager, M., Rappaport, E. F., Wood, A. C., McGrady, P. W., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.019 · Cited by 388
A mechanistic classification of clinical phenotypes in neuroblastoma
Ackermann, S., Cartolano, M., Hero, B., Welte, A., Kahlert, Y., Roderwieser, A., Bartenhagen, C., Walter, E., Gecht, J., Kerschke, L., et al. (2018) · Science · doi:10.1126/science.aat6768 · Cited by 335
Cole, K. A., Huggins, J., Laquaglia, M., Hulderman, C. E., Russell, M. R., Bosse, K., Diskin, S. J., Attiyeh, E. F., Sennett, R., Norris, G., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012351108 · Cited by 249
Metadata
- Authors
- Carr-Wilkinson, J., O'Toole, K., Wood, K. M., Challen, C. C., Baker, A. G., Board, J. R., Evans, L., Cole, M., Cheung, N.-K. V., Boos, J., Köhler, G., Leuschner, I., Pearson, A. D. J., Lunec, J., & Tweddle, D. A.
- Venue
- Clinical Cancer Research
- Published
- 2010-02-15
- Volume
- 16
- Issue
- 4
- Pages
- 1108-1118
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2124857275
- Cited by
- 162
- References
- 4
- FWCI
- 6.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-09-1865
- The paper
- Carr-Wilkinson, J., O'Toole, K., Wood, K. M., Challen, C. C., Baker, A. G., Board, J. R., Evans, L., Cole, M., Cheung, N.-K. V., Boos, J., Köhler, G., Leuschner, I., Pearson, A. D. J., Lunec, J., & Tweddle, D. A. (2010). High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-09-1865
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.